A study to evaluate the safety, tolerability and pharmacokinetics of inhaled Montelukast (MK-0476) in participants with mild or moderate asthma.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants Who Experienced At Least One Adverse Event
Timeframe: Up to 14 days after last dose of study drug
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
Timeframe: Up to 7 days after last dose of study drug
Area Under the Curve From 0 to 24 Hours (AUC 0-24hr) of Montelukast - Single Dose
Timeframe: Up to 24 hours postdose
AUC 0-24hr of Montelukast - Multiple Doses
Timeframe: Up to 24 hours postdose
Maximum Plasma Concentration (Cmax) of Montelukast - Single Dose
Timeframe: Up to 24 hours postdose
Cmax of Montelukast - Multiple Doses
Timeframe: Up to 24 hours postdose
Time to Cmax (Tmax) of Montelukast - Single Dose
Timeframe: Up to 24 hours postdose
Tmax of Montelukast - Multiple Doses
Timeframe: Up to 24 hours postdose
Apparent Terminal Half Life (t1/2) of Montelukast - Single Dose
Timeframe: Up to 24 hours postdose
t1/2 of Montelukast - Multiple Doses
Timeframe: Up to 24 hours postdose
AUC 0-24hr Accumulation Ratio of Montelukast - Multiple Doses
Timeframe: up to 10 days after first dose of study drug
Cmax Accumulation Ratio of Montelukast - Multiple Doses
Timeframe: up to 10 days after first dose of study drug